BUFOMIX EASYHALER 200/6 budesonide/formoterol (eformoterol) fumarate dihydrate 160 ug/4.5 ug per inhalation powder for inhalation dry powder inhaler

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

budesonide, Quantity: 160 microgram/actuation; formoterol fumarate dihydrate, Quantity: 4.5 microgram/actuation

Commercializzato da:

Orion Pharma (AUS) Pty Limited

Forma farmaceutica:

Inhalation, powder for

Composizione:

Excipient Ingredients: lactose monohydrate

Via di somministrazione:

Inhalation

Confezione:

60 inhalations

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

Asthma,BUFOMIX EASYHALER is indicated in adults and adolescents (12 years and older), for the treatment of asthma, to achieve overall asthma control, including the relief of symptoms and the reduction of the risk of exacerbations (see Section 4.2 Dose and method of administration).,Chronic obstructive pulmonary disease (COPD),BUFOMIX EASYHALER is indicated for the symptomatic treatment of moderate to severe COPD (FEV1 less than or equal to 50 percent predicted normal) in adults with frequent symptoms despite long-acting bronchodilator use, and/or a history of recurrent exacerbations. BUFOMIX EASYHALER is not indicated for the initiation of bronchodilator therapy in COPD.

Dettagli prodotto:

Visual Identification: white to yellowish white powder for inhalation in a device metered inhaler with red overcap and dark purple/blue dustcap; Container Type: Inhaler - dry powder; Container Material: Plastic; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

2022-10-28